Milan, January 15, 2024 – BetaGlue Technologies S.p.A. (“BetaGlue” or the “Company”) a clinical stage company developing novel medical device products with a primary focus in the field of loco- regional radiotherapy to treat solid tumour cancers, today announced the appointment of Salvatore Calabrese as the Company’s Chief Financial Officer. Salvatore brings a wealth of…

The Board of Directors welcomes new Board Members Giovanni Cerutti and Luca Melindo who will support the company's future growth The Ordinary Shareholder’s Meeting of BetaGlue Technologies appointed the new Board of Directors: Colin Story, Giovanni Cerutti and Luca Melindo have been appointed Directors of the Company, while Diana Saraceni, Claudio Giuliano, Michel Therin are…